India`s Strides Arcolab gets USFDA nod for HIV tablets
Mumbai (ANTARA News/Asia Pulse) -- Indian pharmaceutical firm Strides Arcolab (BSE:532531) on Wednesday said it has received the nod from the United States Food and Drug Administration (USFDA) for a dose combination of Lamivudine and Stavudine tablets used to treat adults and children who are infected with HIV.
It has received approval from the USFDA for one new drug application for a fixed dose combination of Lamivudine and Stavudine tablets, Strides Arcolab said in a filing to the Bombay Stock Exchange.
"This approval is yet another significant milestone in the front line of approvals for HIV medicines. This, combined with our pipeline of second line drugs will makes us a significant player in the quality, affordable multi-source anti-retro virals (ARV)s business segment," chief executive officer of the Indian operations of Strides, V S Iyer, said.
April 20, 2009